First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
Neha Gupta, Hassan Hatoum, Grace K DyDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAAbstract: Lung cancer is the leading cause of cancer mortality worldwide in both men and women. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more...
Guardado en:
Autores principales: | Gupta N, Hatoum H, Dy GK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/130901e4e4d949f2b1c485b37d7dfbeb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015) -
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Tobias Dechow, et al.
Publicado: (2021) -
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
por: Evelina Miele, et al.
Publicado: (2009) -
First-line therapy of chronic myeloid leukemia – focus on dasatinib
por: Amrein PC
Publicado: (2012) -
A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
por: Jin F, et al.
Publicado: (2016)